Stocks · News reference
Stereotaxis reported positive initial clinical results for Robocath's next-generation robotic system, achieving a 100% clinical success rate with no device-related complications.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Stereotaxis and Canon Medical Systems USA have entered into a collaboration to integrate Canon's Alphenix interventional imaging platform with the Stereotaxis GenesisX Robotic Magnetic Navigation system.
Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established a new robotic center for cardiac arrhythmia treatment using Stereotaxis' Genesis Robotic Magnetic Navigation System.
Stereotaxis, Inc. has announced it will release its financial results for the third quarter of 2026 on November 10, 2026, following the close of U.S. financial markets.
Citizens analyst Daniel Stauder maintains Stereotaxis (AMEX:STXS) with a Market Outperform and lowers the price target from $4 to $3.